Formats
  1. Journal Article (67197)
  2. Meeting Abstract (33961)
  3. Book Section (5131)
  4. Review (3849)
  5. Editorial (2234)
  6. Conference Paper (1529)
  7. Guidelines (682)
  8. Correspondence (676)
  9. Research Letter (563)
  10. Book Whole (346)
  11. Miscellaneous (344)
Groups
  1. Department of Medicine (39434)
  2. GSK Faculty (22620)
  3. Solid Tumor Oncology Division (22241)
  4. Surgery (21399)
  5. Survivorship Research (15894)
  6. Sloan Kettering Institute Faculty (15707)

More Groups

People
  1. Marc Ladanyi (1332)
  2. Robert Motzer (1247)
  3. Victor Reuter (1229)
  4. Howard Scher (1130)
  5. Sergio Giralt (1065)
  6. Murray Brennan (1059)

More People

Years
  1. 2026 (7)
  2. 2025 (2817)
  3. 2024 (5600)
  4. 2023 (5809)
  5. 2022 (6169)
  6. 2021 (5720)

More Years

Publications
  1. Journal of Clinical Oncology (8683)
  2. Blood (5169)
  3. Cancer Research (2703)
  4. International Journal of Radiation Oncology, Biology, Physics (2619)
  5. Laboratory Investigation (1890)
  6. Modern Pathology (1817)

More Publications

Publishers
  1. Elsevier Inc. (13940)
  2. American Society of Clinical Oncology (9275)
  3. Springer (7226)
  4. Nature Publishing Group (6437)
  5. American Association for Cancer Research (6026)
  6. American Society of Hematology (5550)

More Publishers

Results (116512)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Uncovering the hidden structure of T cell compositions in peripheral blood after immune checkpoint inhibitor
    Meeting Abstract

    Peng, X.; Lee, J.; Adamow, M.; Maher, C.; Callahan, M.; Panageas, K.; Shen, R.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Signal-regulatory protein alpha (SIRPĪ±) confers tumor cell resistance to anti-tumor immunity
    Meeting Abstract

    Weng, C. H.; Hamadene, L.; Eghbali, S.; Venkatesh, D.; Monette, S.; Mangarin, L.; Samaan, F.; Liu, C.; Holland, P.; Wolchok, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Trial in progress: A phase 1/2 open-label study (IOV-GM1-201) of talen-mediated PD-1-inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
    Meeting Abstract

    Betof, A.; Wise-Draper, T.; He, K.; Sarnaik, A.; Thompson, J.; Finckenstein, F.; Hari, P.; Jagasia, M.; Desai, A.; Suzuki, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Immune checkpoint blockade enhances cyclophosphamide induced anti-tumor immunity in a preclinical melanoma model
    Meeting Abstract

    George, M.; Betof, A.; Merghoub, T.; Hamadene, L.; Hirschhorn, D.; Houghton, A.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Lag3 blockade in combination with GITR improves anti-tumor immune responses in a preclinical melanoma model
    Meeting Abstract

    Maniyar, R.; Zappasodi, R.; Elhanati, Y.; St Jean, S.; Carrasco, S.; Greenbaum, B.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Apr-246 induces an increase in tumor immunogenicity in a p53 independent manner
    Meeting Abstract

    Venkatesh, D.; Michels, J.; Lu, C.; Budhu, S.; George, M.; Ouerfelli, O.; Abrahmsen, L.; Zappasodi, R.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • LDH inhibition improves response to CTLA-4 blockade by enhancing effector T cell activity and impairing regulatory T cell suppression
    Meeting Abstract

    Verma, S.; Serganova, I.; Budhu, S.; Dong, L.; Mangarin, L.; Ko, M.; Blasberg, R.; Zappasodi, R.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Targeting LSD1 rescues MHC-I antigen presentation and overcomes resistance to PD-L1 blockade therapy in small cell lung cancer
    Meeting Abstract

    Nguyen, E.; Chow, A.; Rudin, C.; Sen, T.; Taniguchi, H.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Pharmacokinetic and pharmacodynamic data from a phase 1 study of CI-8993 anti-vista antibody in patients with advanced solid tumors
    Meeting Abstract

    Noelle, R.; Johnson, M.; Rodon, J.; Zauderer, M.; Lewis, L.; Severgnini, M.; Parker, J.; Lane, M.; von Roemeling, R.; Martin, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • ITIL-306-201: A multicenter, first-in-human phase 1a/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor
    Meeting Abstract

    Ward, J.; Ghobadi, A.; Liao, J.; Schoenfeld, A.; Tykodi, S.; Jiang, Y.; Le Gall, J.; Alvarez-Rodriguez, R.; Sherman, M.; Singson, T.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save